| Revised response criteria for malignant lymphoma BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ... Journal of clinical oncology 25 (5), 579-586, 2007 | 5367 | 2007 |
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... New England Journal of Medicine 369 (6), 507-516, 2013 | 1909 | 2013 |
| Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients … W Hiddemann, M Kneba, M Dreyling, N Schmitz, E Lengfelder, R Schmits, ... Blood 106 (12), 3725-3732, 2005 | 1733 | 2005 |
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ... New England Journal of Medicine 370 (11), 1008-1018, 2014 | 1249 | 2014 |
| A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma E Hoster, M Dreyling, W Klapper, C Gisselbrecht, A Van Hoof, ... Blood, The Journal of the American Society of Hematology 111 (2), 558-565, 2008 | 1116 | 2008 |
| Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ... Annals of oncology 26, v116-v125, 2015 | 1110 | 2015 |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ... Annals of Oncology 32 (1), 23-33, 2021 | 988 | 2021 |
| Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆ M Dreyling, M Ghielmini, S Rule, G Salles, M Ladetto, SH Tonino, ... Annals of Oncology 32 (3), 298-308, 2021 | 944* | 2021 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 851 | 2022 |
| Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long … G Lenz, M Dreyling, E Hoster, B Wörmann, U Dührsen, B Metzner, ... Journal of Clinical Oncology 23 (9), 1984-1992, 2005 | 789 | 2005 |
| Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in … M Dreyling, G Lenz, E Hoster, A Van Hoof, C Gisselbrecht, R Schmits, ... Blood 105 (7), 2677-2684, 2005 | 769 | 2005 |
| The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with … R Forstpointner, M Dreyling, R Repp, S Hermann, A Hänel, B Metzner, ... Blood 104 (10), 3064-3071, 2004 | 757 | 2004 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 718 | 2019 |
| Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective … A Pastore, V Jurinovic, R Kridel, E Hoster, AM Staiger, M Szczepanowski, ... The lancet oncology 16 (9), 1111-1122, 2015 | 663 | 2015 |
| Treatment of older patients with mantle-cell lymphoma HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ... New England Journal of Medicine 367 (6), 520-531, 2012 | 644 | 2012 |
| Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up DA Eichenauer, BMP Aleman, M André, M Federico, M Hutchings, ... Annals of Oncology 29, iv19-iv29, 2018 | 618* | 2018 |
| Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide … R Forstpointner, M Unterhalt, M Dreyling, HP Böck, R Repp, H Wandt, ... Blood 108 (13), 4003-4008, 2006 | 556 | 2006 |
| Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study M Dreyling, W Jurczak, M Jerkeman, RS Silva, C Rusconi, M Trneny, ... The Lancet 387 (10020), 770-778, 2016 | 535 | 2016 |
| Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study G Salles, J Duell, EG Barca, O Tournilhac, W Jurczak, AM Liberati, Z Nagy, ... The Lancet Oncology 21 (7), 978-988, 2020 | 516 | 2020 |
| Improvement of overall survival in advanced stage mantle cell lymphoma A Herrmann, E Hoster, T Zwingers, G Brittinger, M Engelhard, P Meusers, ... Journal of Clinical Oncology, 2008 | 513 | 2008 |
